Cargando…
Risk Factors, Prophylaxis, and Treatment of Venous Thromboembolism in Congenital Heart Disease Patients
Congenital heart disease (CHD) is a common condition in the pediatric population, affecting up to 1% of all live births (i.e., around 40,000 newborns/year in the United States). Although CHD does have a wide range of severity, by the age of 5 years approximately 80% of patients will require at least...
Autores principales: | Silvey, Michael, Brandão, Leonardo R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476169/ https://www.ncbi.nlm.nih.gov/pubmed/28674685 http://dx.doi.org/10.3389/fped.2017.00146 |
Ejemplares similares
-
Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022) -
Venous Thromboembolism Prophylaxis Use by Pediatric Orthopedic Surgeons in Canada for the Pediatric Orthopedic Surgical Population
por: Curwin, Jenna, et al.
Publicado: (2022) -
Treatment of Venous Thromboembolism in Pediatric Patients
por: Malec, Lynn, et al.
Publicado: (2017) -
Venous thromboembolism prophylaxis on flights
por: Marques, Marcos Arêas, et al.
Publicado: (2018) -
Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism
por: Mahajerin, Arash, et al.
Publicado: (2017)